About
Hepta Bio develops a liquid biopsy-native AI platform that analyzes epigenetic patterns in cell-free DNA from blood to enable non-invasive diagnosis and monitoring of chronic liver diseases such as metabolic dysfunction-associated steatohepatitis (MASH).
Explore Hepta Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.